Neumora Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Neumora Therapeutics (NMRA).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

7Buy

1Hold

2Sell

Consensus RatingBuy# Analysts10Avg. Consensus PT$6Upside to Avg. PT+1178.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 13, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$7→$5
Jun 18, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$6→$4
Jun 16, 2026	Needham	Ami Fadia	PT Cut	Buy	$8→$5
Jun 16, 2026	HC Wainwright & Co.	Douglas Tsao	PT Cut	Buy	$18→$7
Mar 31, 2026	Guggenheim	Yatin Suneja	Maintained	Buy	$14
Mar 31, 2026	Needham	Ami Fadia	Maintained	Buy	$8
Feb 17, 2026	William Blair	Myles Minter	Upgrade	Market Perform→Outperform	—
Jan 12, 2026	Leerink Partners	Marc Goodman	Initiate	Outperform	$8
Dec 1, 2025	RBC Capital	Brian Abrahams	Upgrade	Sector Perform→Outperform	$4→$7
Nov 17, 2025	Stifel	Paul Matteis	PT Raise	Hold	$2→$3
Oct 28, 2025	Needham	Ami Fadia	PT Raise	Buy	$6→$8
Oct 27, 2025	Guggenheim	Yatin Suneja	Upgrade	Neutral→Buy	$14
Sep 16, 2025	JP Morgan	Tessa Romero	Downgrade	Neutral→Underweight	—
Jul 16, 2025	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$4→$5
May 13, 2025	Needham	Ami Fadia	Maintained	Buy	$5
Apr 10, 2025	Needham	Ami Fadia	Maintained	Buy	$5
Apr 2, 2025	B of A Securities	Geoff Meacham	Downgrade	Buy→Underperform	$7→$1
Mar 10, 2025	Guggenheim	Yatin Suneja	Downgrade	Buy→Neutral	—
Mar 7, 2025	Stifel	Paul Matteis	Downgrade	Buy→Hold	$6→$2
Mar 7, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$18

Analyst Ratings News

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.

Vandana Singh

PRO
RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5

RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $7 to $5.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4

Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $6 to $4.

Benzinga Newsdesk

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey. See full list here.

Avi Kapoor

PRO
Needham Maintains Buy on Neumora Therapeutics, Lowers Price Target to $5

Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $8 to $5.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. analyst Douglas Tsao maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $18 to $7.

Benzinga Newsdesk

Neumora Therapeutics Inc

Neumora Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Why Is BioAge Labs Stock Sinking Friday?

PRO
RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5

PRO
Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

PRO
Needham Maintains Buy on Neumora Therapeutics, Lowers Price Target to $5

PRO
HC Wainwright & Co. Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7

People Also Watch

People Also Watch

Neumora Therapeutics Inc

Neumora Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Why Is BioAge Labs Stock Sinking Friday?

PRORBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5

PROMizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

PRONeedham Maintains Buy on Neumora Therapeutics, Lowers Price Target to $5

PROHC Wainwright & Co. Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5

PRO
Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4

PRO
Needham Maintains Buy on Neumora Therapeutics, Lowers Price Target to $5

PRO
HC Wainwright & Co. Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7